This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioSante Satisfied to Be Second

BioSante Pharmaceuticals (BPA) is a sexy stock.

The standout opportunity amidst the small drug company's well-stocked pipeline of hormone therapy products is a testosterone gel that, if approved for sale, would be used by menopausal women to boost their flagging sex drive.

The commercial market for legitimate products to treat "female sexual dysfunction" barely exists today. This stands in stark contrast to the mountains of cash forked over by men for drugs like Viagra, Cialis and Levitra.

But gender inequality over sexual dysfunction treatments is about to change, which puts BioSante in a sweet spot. And at a current stock price of $8.91 and a market cap of $164 million, the company is both underappreciated by investors and undervalued given the significant commercial potential for products like LibiGel.

There are a bunch of reasons to like the BioSante story. For starters, there is well-established science behind LibiGel, and with that foundation comes a relatively lower risk that the product blows up. Doctors have long understood that a lower-than-normal level of the hormone testosterone contributes to a waning desire for sex in women, especially women nearing, or in, menopause. When testosterone levels are boosted back to normal levels, a woman's desire for sex also returns to more normal levels.

Pfizer (PFE - Get Report) spent many years trying to prove that Viagra would also work for women, but while the drug did increase blood flow to the vagina (it does the same for a man's penis), the drug giant found that women who took Viagra did not have an increased desire for sex. This bolstered the belief that hormones play a larger role in female sex drive and forced Pfizer earlier this year to stop testing Viagra for women.

Competitor's Success Bolsters LibiGel

The best evidence of LibiGel's efficacy, so far, actually comes from a larger competitor. Procter & Gamble (PG - Get Report) is developing Intrinsa, a testosterone patch that treats female sexual dysfunction. In May, the company announced positive results from a pivotal phase III study of 562 women, who had had their ovaries removed and were therefore in menopause. Women in the study who wore the testosterone patch reported a 74% increase in the frequency of satisfying sexual activity as well as a 56% increase in sexual desire vs. baseline. Results from the study were statistically significant, and Procter & Gamble is expected to seek Intrinsa marketing approval from the Food and Drug Administration by the end of the year.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
PFE $34.28 0.00%
PG $79.95 0.00%
AAPL $132.54 0.00%
FB $80.54 0.00%
GOOG $540.11 0.00%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs